How the bone environment affects drug resistance in prostate cancer
Influence of bone microenvironment on drug resistance in prostate cancer bone metastasis
This study is looking at how prostate cancer that has spread to the bones can become resistant to treatments like enzalutamide, and it aims to find new ways to make these treatments work better for patients dealing with this tough situation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-10757411 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind drug resistance in prostate cancer that has spread to the bones. It focuses on how the bone microenvironment influences the effectiveness of treatments like enzalutamide, which is commonly used for advanced prostate cancer. By studying the role of specific proteins in bone cells, the research aims to uncover new strategies to overcome resistance and improve treatment outcomes for patients with bone metastases. The study utilizes mouse models to explore these interactions and their implications for human patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are prostate cancer patients who have developed resistance to hormonal therapies and have bone metastases.
Not a fit: Patients with early-stage prostate cancer or those without bone metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer patients with bone metastases, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown that understanding the tumor microenvironment can lead to breakthroughs in cancer treatment, suggesting that this approach has the potential for success.
Where this research is happening
Toledo, United States
- University of Toledo Health Sci Campus — Toledo, United States (Active)
Researchers
- Principal investigator: Li, Xiaohong — University of Toledo Health Sci Campus
- Study coordinator: Li, Xiaohong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.